Status:

ACTIVE_NOT_RECRUITING

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

Lead Sponsor:

AbbVie

Conditions:

Bipolar I Disorder

Bipolar II Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participant...

Eligibility Criteria

Inclusion

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder without psychotic features based on the Mini International Neuropsychiatric Interview (MINI), with a current depressive episode of at least 4 weeks and not exceeding 12 months.
  • Have a minimum score of 20 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • Have a minimum score of 2 on Item 1 of the HAMD-17 at screening.

Exclusion

  • Positive urine drug screen (UDS) result at screening.
  • Treated with any investigational drug within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug, is currently enrolled in another clinical study, or was previously enrolled in this study.
  • Current use of any antipsychotic, antidepressant, anticonvulsant, mood stabilizer, herb, or over-the-counter medication with psychoactive potential within 1 week or 5 half-lives of the medication (whichever is longer).
  • Prior exposure to ABBV-932 within 90 days prior to baseline.

Key Trial Info

Start Date :

October 15 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT06605599

Start Date

October 15 2024

End Date

December 1 2025

Last Update

December 17 2025

Active Locations (40)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (40 locations)

1

Harmonex /ID# 267504

Dothan, Alabama, United States, 36303

2

Advanced Research Center /ID# 267716

Anaheim, California, United States, 92805

3

Axiom Research /ID# 267518

Colton, California, United States, 92324

4

Collaborative Neuroscience Research - Garden Grove /ID# 267654

Garden Grove, California, United States, 92845

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder | DecenTrialz